Submucosal Injection Solution for Endoscopic Resection in Gastrointestinal Tract: A Traditional and Network Meta-Analysis

Table 1

Characteristics of participants.

Study	Group	Case	Age	Sex	Size	Site	Method	Type
				(M/F)	(mm)
Lee et al., 2006 [10]	Fibrinogen	36	61.4 ± 11.5	27/9	19.2 ± 6.3	Gastric, proximal 2/3 (11), distal 1/3 (25)	EMR	Adenoma (24), adenocarcinoma (12)
	NS	36	59.7 ± 11.2	21/15	16.8 ± 6.1	Gastric, proximal 2/3 (12), distal 1/3 (24)		Adenoma (25), adenocarcinoma (11)
Hurlstone et al., 2008 [11]	Dextrose	82	56 (29–84)^*	42/40	18 (6–35)^*	Colon, left (33), right (49)	EMR	LGD (58), HGD (19), carcinoma (5)
	0.4% SHA	81	58 (32–83)^*	39/42	20 (4–40)^*	Colon, left (36), right (45)		LGD (59), HGD (18), carcinoma (4)
Katsinelos et al., 2008 [12]	Dextrose	45	65 (42–82)^*	20/25	>10	Rectosigmoid, rectum (27), sigmoid (18)	EMR	LGD (16), MGD (18), HGD (9), carcinoma (2)
	NS	47	69 (41–92)^*	27/20		Rectosigmoid, rectum (27), sigmoid (20)		LGD (23), MGD (13), HGD (10), carcinoma (1)
Yamamoto et al., 2008 [13]	0.4% SHA	69	65.3 ± 8.1	57/12	5–20^*	Gastric, proximal (8), body (30), distal (31)	ESD & EMR	Adenoma (18), adenocarcinoma (58)
	NS	70	66.1 ± 8.4	51/19		Gastric, proximal (8), body (28), distal (34)		Adenoma (17), adenocarcinoma (53)
Kizu et al., 2010 [14]	0.4% SHA	53	—	—	<20	Gastric	ESD	—
	NS	52
Moss et al., 2010 [15]	SG	41	69 (64–76)^#	22/19	40 (25–45)^#	Colon, proximal to hepatic flexure (17)	EMR	Tubular (18), tubulovillous (16), sessile serrated adenoma (7)
	NS	39	67 (62–78)^#	23/16	35 (30–50)^#	Colon, proximal to hepatic flexure (14)		Tubular (11), tubulovillous (22), sessile serrated adenoma (6)
Fasoulas et al., 2012 [16]	HES	25	68 (43–82)^*	16/9	4.5 (3.2–7)^*	Colorectal, rectum (19), ascending colon (3), cecum (3)	EMR	Paris classification, O-II a (19), O-II b (6)
	NS	24	67 (48–88)^*	8/16	4.6 (3.3–7.2)^*	Colorectal, rectum (18), ascending colon (3), cecum (3)		Paris classification, O-II a (21), O-II b (3)
Kishihara et al., 2012 [17]	0.2% SHA	46	61.0 ± 9.0	21/25	11.3 ± 3.0	Colorectal, proximal (20), distal (22), rectum (4)	EMR	Adenoma (39), adenocarcinoma (7)
	NS	48	65.0 ± 8.0	32/16	12.5 ± 4.0	Colorectal, proximal (26), distal (16), rectum (6)		Adenoma (40), adenocarcinoma (8)
Yoshida et al., 2012 [18]	0.13% SHA	93	66 (23–85)^*	62/31	8.9 (8–16)^*	Colorectal, cecum to descending colon (49), rectum to sigmoid (44)	EMR	Adenoma (84), adenocarcinoma (9)
	NS	96	67 (35–89)^*	63/33	8.2 (5–15)^*	Colorectal, cecum to descending colon (50), rectum to sigmoid (46)		Adenoma (92), adenocarcinoma (4)
Kim et al., 2013 [19]	0.4% SHA	29	62.6 ± 9.2	25/12	14.2 ± 5.47	Gastric, antrum (23), angle (3), body (11)	ESD	Adenoma (31), atypia (1), adenocarcinoma (5)
	NS	34	62.4 ± 9.9	26/13	13.5 ± 4.35	Gastric, antrum (29), angle (3), body (7)		Adenoma (31), atypia (1), adenocarcinoma (7)
Sumiyama et al., 2014 [20]	Mesna	53	—	41/9	19.5 ± 11.5	Gastric, upper (7), middle (25), lower (21)	ESD	Adenoma (7), adenocarcinoma (46)
	NS	53	—	41/9	17.1 ± 10.1	Gastric, upper (12), middle (20), lower (20)		Adenoma (5), adenocarcinoma (47)

E, epinephrine; HES, hydroxyethyl starch; SG, succinylated gelatin.
^*Median (range), ^#median (interquartile range).
LGD, low-grade dysplasia; MGD, moderate-grade dysplasia; HGD, high-grade dysplasia.